Tags

Type your tag names separated by a space and hit enter

Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study.

Abstract

This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Service de Neurologie, Hôpital Saint Antoine, Paris, France.

    , , ,

    Source

    MeSH

    Administration, Oral
    Adult
    Analgesics
    Aspirin
    Double-Blind Method
    Drug Therapy, Combination
    Female
    Humans
    Lysine
    Male
    Metoclopramide
    Middle Aged
    Migraine Disorders

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    7954760

    Citation

    Chabriat, H, et al. "Combined Oral Lysine Acetylsalicylate and Metoclopramide in the Acute Treatment of Migraine: a Multicentre Double-blind Placebo-controlled Study." Cephalalgia : an International Journal of Headache, vol. 14, no. 4, 1994, pp. 297-300.
    Chabriat H, Joire JE, Danchot J, et al. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia. 1994;14(4):297-300.
    Chabriat, H., Joire, J. E., Danchot, J., Grippon, P., & Bousser, M. G. (1994). Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia : an International Journal of Headache, 14(4), pp. 297-300.
    Chabriat H, et al. Combined Oral Lysine Acetylsalicylate and Metoclopramide in the Acute Treatment of Migraine: a Multicentre Double-blind Placebo-controlled Study. Cephalalgia. 1994;14(4):297-300. PubMed PMID: 7954760.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. AU - Chabriat,H, AU - Joire,J E, AU - Danchot,J, AU - Grippon,P, AU - Bousser,M G, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 297 EP - 300 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 14 IS - 4 N2 - This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks. SN - 0333-1024 UR - https://www.unboundmedicine.com/medline/citation/7954760/full_citation L2 - http://journals.sagepub.com/doi/full/10.1046/j.1468-2982.1994.1404297.x?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -